Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Novartis
Covington
Healthtrust
Federal Trade Commission
Julphar
Dow
Farmers Insurance
Colorcon

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,659,285

« Back to Dashboard

Which drugs does patent 7,659,285 protect, and when does it expire?

Patent 7,659,285 protects NUPLAZID and is included in one NDA.

This patent has thirty patent family members in twenty-one countries.
Summary for Patent: 7,659,285
Title:Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
Inventor(s): Weiner; David M. (San Diego, CA), Davis; Robert E. (San Diego, CA), Brann; Mark R. (Rye, NH), Andersson; Carl-Magnus A. (Hjarup, SE), Uldam; Allan K. (Ballerup, DK)
Assignee: Acadia Pharmaceuticals, Inc. (San Diego, CA)
Application Number:11/416,855
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,659,285

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,659,285

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,008,323 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Subscribe
9,566,271 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Subscribe
7,601,740 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Subscribe
8,618,130 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Subscribe
7,713,995 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Subscribe
8,227,487 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Subscribe
7,994,193 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Subscribe
7,732,462 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Subscribe
9,211,289 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Subscribe
8,377,959 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,659,285

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2009000 ➤ Subscribe
Slovenia 1587789 ➤ Subscribe
Singapore 170617 ➤ Subscribe
Russian Federation 2465267 ➤ Subscribe
Russian Federation 2008115009 ➤ Subscribe
Russian Federation 2332401 ➤ Subscribe
Russian Federation 2005125918 ➤ Subscribe
Portugal 1587789 ➤ Subscribe
New Zealand 541146 ➤ Subscribe
Mexico PA05007568 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Johnson and Johnson
Farmers Insurance
Boehringer Ingelheim
Dow
Fuji
Citi
US Army
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot